132039An innovative inhaler for improved asthma managementClosedFeasibility StudiesInnovate UKAn estimated 5.4 million people across the UK have asthma. Non-compliance with inhaled corticosteroid (ICS) treatment regimens is believed to contribute to over 61% of deaths from asthma. 3D Design Engineering Ltd plan to develop an innovative inhaler to aid patient compliance with their prescribed drug regime. The impacts of enabling greater compliance with ICS treatments would be manifold; a reduction in morbidity and mortality would be expected, as would a reduction in the costs to the NHS associated with asthma, which costs the NHS an estimated £1 billion a year with total associated costs to the UK estimated from £2.3 billion per year to over £6 billion per year. Economic burden of asthma results from poorly controlled disease and asthma exacerbations, which contribute to increased direct medical expenditures related to emergency care as well as indirect costs of lost work time and lost productivity. Over 12.7 million working days are lost to asthma each year.